ImmuCell Corporation (ICCC) Stock

ImmuCell Corporation, headquartered in Portland, Maine, is a leading animal health company dedicated to advancing the well-being and productivity of dairy and beef cattle both domestically and globally. Specializing in the development, manufacturing, and marketing of innovative products, ImmuCell's offerings cater to various aspects of bovine health management. The company's flagship product, First Defense, is an orally administered preventive solution designed to combat scours in newborn dairy and beef calves. Additionally, Tri-Shield First Defense provides passive antibody protection against pathogens such as E. coli, coronavirus, and rotavirus, bolstering calf health during crucial early stages.

ImmuCell's product portfolio extends beyond preventive measures to include diagnostic tools like the California Mastitis Test, essential for detecting somatic cell counts in milk and pinpointing udder quarters affected by mastitis. The company also addresses nutritional needs with Dual-Force First Defense, incorporating a whey protein concentrate tailored for the nutritional and feed supplement markets. Furthermore, ImmuCell is actively involved in developing Re-Tain, an intramammary treatment utilizing Nisin to combat subclinical mastitis in lactating dairy cows, underscoring its commitment to advancing veterinary healthcare solutions.

Established in 1982, ImmuCell Corporation leverages decades of expertise to distribute its products through a network of animal health distributors, ensuring widespread availability and accessibility to its innovative solutions. With a steadfast dedication to enhancing bovine health outcomes through pioneering research and development, ImmuCell continues to drive advancements in veterinary medicine, reinforcing its position as a key player in the global animal health industry.